According to the Zhitong Finance App, Laimei Pharmaceutical (300006.SZ) issued an announcement. The cumulative deviation value of the closing price increase of the company's shares exceeded 30% for three consecutive trading days on October 12, October 13, and October 14, 2026. According to the relevant provisions of the “Shenzhen Stock Exchange Trading Rules”, this is an abnormal fluctuation in stock trading. The company is concerned that the market and media have recently paid attention to the clinical trial of the company's nano-carbon and iron suspension injection (CNSi-Fe) (hereinafter referred to as nano-carbon iron). The matter mainly stems from the fact that Sichuan Yingrui Pharmaceutical Technology Co., Ltd. (hereinafter referred to as Yingrui Pharmaceutical), a holding subsidiary of the company, recently published its self-developed academic paper on nano-carbon iron phase I clinical trials in relevant academic journals and the interpretation of clinical trial results or individual case results disclosed by relevant partner hospitals.
Up to now, nano-carbon-iron combined radiotherapy is still in phase II clinical trials. Subsequent radiotherapy phase II clinical trial results are still needed to advance core aspects such as applying for breakthrough treatment certification, or conducting phase III clinical trials and applying for drug marketing approval (NDA). There are major uncertainties in all of the above core aspects. There are risks such as the results of the phase II clinical trial falling short of expectations, not being able to apply for or be approved for breakthrough treatment certification, not being able to conduct or complete the phase III clinical trial, not being able to submit or obtain approval for an NDA, and delays in the review and approval process. Drug research and development is a long-term process. It is expected that it will not have a significant impact on the company's business performance in the short term, from early research and development, clinical trial execution to marketing approval, and the process is easily affected by various uncertainties. There is uncertainty about whether it can be successfully approved for marketing and approval time. If subsequent products can be approved for listing, their commercialization will still be affected by multiple factors such as drug demand, market competition, and sales channels. There is also uncertainty about whether expected sales can be achieved and the impact on the company's future business performance.